576P - Wilms tumor gene (WT-1) expression in female patients with unfavorable subset of cancer of unknown primary site

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Carcinoma of Unknown Primary Site
Translational Research
Presenter Makoto Kodaira
Citation Annals of Oncology (2016) 27 (suppl_9): ix184-ix189. 10.1093/annonc/mdw603
Authors M. Kodaira1, K. Yonemori2, T. Shimoi2, A. Shimomura2, M. Yunokawa2, C. Shimizu2, Y. Fujiwara2, K. Tamura2
  • 1Medical Oncology, JIKOKAI Kodaira Hospital, 330-0052 - Toda/JP
  • 2Breast And Medical Oncology, National Cancer Center Hospital, Tokyo/JP

Abstract

Background

Wilms tumor gene (WT-1) expression has been reported in most adenocarcinoma of ovary and peritoneum. Clinical characteristics of adenocarcinoma with Wilms tumor gene (WT-1) expression in female patients with unfavorable subset of cancer of unknown primary site (CUP) have not been cleared.

Methods

The female patients diagnosed with unfavorable subset of CUP under the standard clinical and pathological examination, histological type of adenocarcinoma with positive WT-1 expression, and received systemic chemotherapy as an initial therapy, were enrolled in this study (WT-1 positive U-CUP). Clinical date was collected from the date base and electronic medical record from Apr 2009 to Mar 2014. Descriptive and statistical analyses of WT-1 positive U-CUP in our institution were conducted retrospectively.

Results

Four hundred and fifteen patients with suspected CUP were referred to National Cancer Center in the study period. Of these, 7 patients were enrolled in this study. The median age was 69 (56-78) years, performance status of all patients were 0 or 1. All patients had multiple nodal metastatic diseases, and one patient had abdominal mass. All patients were classified into unfavorable subset of CUP. All patients received carboplatin and paclitaxel based chemotherapy, and all patients (100%) showed objective response. Median overall survival and progression free survival of WT-1 positive U-CUP were 1460 days (95% CI: 792-2127 days), and 309 days (95%CI: 302- 315 days) respectively.

Conclusions

This is the first report of the favorable clinical outcome of the WT-1 positive U-CUP. Further investigation to clear the clinical similarities between WT-1 expression in CUP and the primary cancer of ovary and peritoneum is required to provide information for selecting optimal treatment for this new favorable subset.

Clinical trial indentification

Legal entity responsible for the study

National Cancer Center Hospital, Tokyo, Japan

Funding

National Cancer Center Hospital, Tokyo, Japan

Disclosure

All authors have declared no conflicts of interest.